Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

HEMO 2 life® improves renal function independent of cold ischemia time in kidney recipients: A comparison with a large multicenter prospective cohort study

Abstract : M101 is an extracellular hemoglobin isolated from a marine lugworm and is present in the medical device HEMO2 life®. The clinical investigation OXYOP was a paired kidney analysis (n = 60) designed to evaluate the safety and performance of HEMO2 life® used as an additive to preservation solution in renal transplantation. The secondary efficacy endpoints showed less delayed graft function (DGF) and better renal function in the HEMO2 life® group but due to the study design cold ischemia time (CIT) was longer in the contralateral kidneys.
Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03608474
Contributor : Geneviève Michel Connect in order to contact the contributor
Submitted on : Monday, March 14, 2022 - 5:48:56 PM
Last modification on : Thursday, June 16, 2022 - 3:27:26 AM

Identifiers

Citation

yannick Le Meur, Eric Delpy, Felix Renard, Thierry Hauet, Lionel Badet, et al.. HEMO 2 life® improves renal function independent of cold ischemia time in kidney recipients: A comparison with a large multicenter prospective cohort study. Artificial Organs, Wiley, 2021, ⟨10.1111/aor.14141⟩. ⟨hal-03608474⟩

Share

Metrics

Record views

15